Laurie Stelzer
Director/Board Member chez PMV PHARMACEUTICALS, INC.
Profil
Laurie D.
Stelzer is currently the Director at Spyre Therapeutics, Inc., Independent Director at PMV Pharmaceuticals, Inc., and Chief Financial Officer at ReNAgade Therapeutics, Inc. She previously served as an Independent Non-Executive Director at Surface Oncology, Inc., Director at Longboard Pharmaceuticals, Inc., Treasurer & Head-Global Accounting at Amgen, Inc., Chief Financial Officer & Executive Vice President at Arena Pharmaceuticals, Inc., Chief Financial Officer & Senior Vice President at Halozyme Therapeutics, Inc., and Senior VP-Finance & Head-Investor Relations at Shire Plc.
She also served as the Chief Financial Officer at Mirati Therapeutics, Inc. and Senior VP-Finance & Head-Investor Relations at Shire, Inc. Ms. Stelzer received her undergraduate degree from Arizona State University and her MBA from UCLA Anderson School of Management.
Postes actifs de Laurie Stelzer
| Sociétés | Poste | Début |
|---|---|---|
| PMV PHARMACEUTICALS, INC. | Director/Board Member | 01/08/2020 |
| SPYRE THERAPEUTICS, INC. | Director/Board Member | 27/11/2023 |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Director of Finance/CFO | - |
Anciens postes connus de Laurie Stelzer
| Sociétés | Poste | Fin |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Director/Board Member | 08/09/2023 |
| MIRATI THERAPEUTICS | Director of Finance/CFO | 08/09/2023 |
| ARENA PHARMACEUTICALS | Director of Finance/CFO | 01/03/2022 |
| HALOZYME THERAPEUTICS, INC. | Director of Finance/CFO | 01/03/2020 |
Shire, Inc.
 Shire, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire, Inc. develops and markets medicines for patients with rare diseases. The private company is based in Lexington, KY. | Public Communications Contact | 01/01/2015 |
Formation de Laurie Stelzer
| Arizona State University | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| PMV PHARMACEUTICALS, INC. | Commercial Services |
| LONGBOARD PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Shire, Inc.
Shire, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire, Inc. develops and markets medicines for patients with rare diseases. The private company is based in Lexington, KY. | Health Technology |
Renagade Therapeutics, Inc.
Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Health Technology |
